All In Biotech

Drug Trial Radar · NCT06666855

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

A Phase III Study Including a Single-Arm, Open-Label, Multi-Dose PK Study Cohort and a Randomized, Evaluator-Masked, Active Drug Controlled, Parallel Group, Multicenter, Bridging Study Cohort With a Long-term Follow-up Phase Assessing the Efficacy and Safety of DE-117B Eye Drops in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 345 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

345

Actual

Start

Nov 28, 2024

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study. Subjects diagnosed with POAG (Primary Open Angle Glaucoma) or OHT (Ocular Hypertension) who meet eligibility criteria will washout of their current IOP lowering medication(s), if any. The study will investigate plasma pharmacokinetics of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension. It will investigate the safety of multi-dose 0.002% DE-117B eye drops (1 drop at a time administered once daily for 7 days) in Chinese subjects with primary open angle glaucoma or ocular hypertension. There will be a bridging cohort and extension follow-up phase

Conditions

  • Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • DE-117B Eye DropsDrug

    Investigational Product: 0.002% DE-117B Eye Drops

  • LatanoprostDrug

    Active Control: 0.005% Latanoprost Eye Drops

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intraocular Pressure (IOP) at Week 4Time frame: Week 4

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital, Capital Medical University

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Zhongshan Ophthalmic Center

    Guangzhou, China

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • Daqing People's Hospital

    Heilongjiang, China

  • Jinan Second People's Hospital (Jinan eye hospital)

    Jinan, China

  • The Second Hospital & Clinical Medicial Lanzhou University

    Lanzhou, China

  • Luoyang third people's hospital

    Luoyang, China

  • Qingdao Eye Hospital of Shandong First Medical University

    Qingdao, China

  • Shanghai Eye Disease Prevention And Treatment Center/Shanghai Eye Hospital

    Shanghai, China

  • Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong

    Shantou, China

  • Shanxi eye hospital

    Shanxi, China

  • Aier Eye Hospital (Liaoning)

    Shenyang, China

  • The 4th People's Hospital of Shenyang

    Shenyang, China

  • Shenzhen Eye Hospital

    Shenzhen, China

  • Tianjin Eye Hospital

    Tianjin, China

  • Wuhan Aier Eye Hospital

    Wuhan, China

  • Wuhan Puren Hospital

    Wuhan, China

  • Zhongnan Hospital Affiliated to Wuhan University

    Wuhan, China

  • Wuxi Second People's Hospital

    Wuxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.